Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
2(25%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_2
2
25%
Ph not_applicable
3
38%
Ph phase_4
3
38%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
2(25.0%)
Phase 4Post-market surveillance
3(37.5%)
N/ANon-phased studies
3(37.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

8

all time

Status Distribution
Active(2)
Completed(4)
Other(2)

Detailed Status

Completed4
Recruiting2
unknown2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (25.0%)
Phase 43 (37.5%)
N/A3 (37.5%)

Trials by Status

completed450%
recruiting225%
unknown225%

Recent Activity

2 active trials
Showing 5 of 8
recruitingphase_4

Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome

NCT07350018
recruitingphase_4

Prophylactic Minimally Invasive Surfactant Evaluation

NCT06007547
completedphase_2

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

NCT02452476
unknownphase_2

Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19

NCT04384731
unknownphase_4

Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.

NCT03521063
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07350018Phase 4

Calfactant vs Poractant Alfa Using a Less Invasive Technique in Preterm Infants With Respiratory Distress Syndrome

Recruiting
NCT06007547Phase 4

Prophylactic Minimally Invasive Surfactant Evaluation

Recruiting
NCT02452476Phase 2

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

Completed
NCT04384731Phase 2

Curosurf® in Adult Acute Respiratory Distress Syndrome Due to COVID-19

Unknown
NCT03521063Phase 4

Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.

Unknown
NCT02834624Not Applicable

Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome

Completed
NCT01860014Not Applicable

Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage

Completed
NCT01852461Not Applicable

Perfusion Index Variability in Respiratory Distress Syndrome

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8